Porous Ag-Cu-CeO₂ nanoparticles: Biosynthesis, cephalexin photodegradation, antifungal activity and primary evaluation of in vitro cancer treatment on MDA-MB-231 cells.

Authors

Hossein Shahdadi, Pouya Ostadrahimi, Mina Sarani, Mahsa Nourbakhsh

Published in

Biochemistry and biophysics reports. Volume 48. Pages 102809. Epub Oct 08, 2026.

Abstract

In the study, silver- and copper-co doped cerium oxide nanoparticles (Ag-Cu-CeO₂ NP) were prepared using Ferula assa-foetida L. extract as a biological reducing factor. Field emission scanning electron microscopy (FESEM) demonstrated a porous surface texture, while powder X-ray diffraction (PXRD) introduced crystalline dimensions of 21.89 nm. Supplementary techniques, including energy-dispersive X-ray (EDX) analysis, Raman, Fourier-transform infrared (FT-IR) spectrometry, and ultraviolet-visible (UV-vis) spectroscopy validated the successful synthesis of the mentioned nanoparticles. The Ag-Cu-CeO₂ NP gained a magnificent degradation rate of 84.92% for cephalexin (CPX) under visible light exposure, following pseudo-first-order kinetics (k = 0.0086 min^-1). The synthesized NP exhibited moderate antifungal performance against Aspergillus flavus (MIC: 36.25 mg mL^-1) and against Neurospora intermedia (MIC: 72.5 mg mL^-1). Moreover, cytotoxicity assessment via MTT assay exhibited dose dependent inhibition of MDA MB 231 breast cancer cells (IC₅₀ = 475.1 μg mL^-1), and also significantly lower toxicity on normal MCF 10 A cells. These findings propose that the nanoparticles demonstrate greater cytotoxic effects on cancerous MDA-MB-231 cells compared to normal MCF-10 A cells. However, these results are preliminary and entirely in vitro; further in vivo validation, comprehensive toxicity evaluation, and mechanistic studies are needed before considering therapeutic applications. Overall, the outcomes indicate that green-synthesized Ag-Cu-CeO₂ NP describe an effective and promising nanomaterial warranting further study for potential biomedical and environmental applications.

PMID:
42893243
Bibliographic data and abstract were imported from PubMed on 18 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.